31,764 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by Amundi

Amundi acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 31,764 shares of the company’s stock, valued at approximately $256,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quest Partners LLC bought a new position in Amneal Pharmaceuticals in the 3rd quarter worth approximately $84,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Amneal Pharmaceuticals in the 4th quarter worth approximately $81,000. Janney Montgomery Scott LLC bought a new position in Amneal Pharmaceuticals in the 4th quarter worth approximately $121,000. Quadrature Capital Ltd bought a new position in Amneal Pharmaceuticals in the 3rd quarter worth approximately $169,000. Finally, Entropy Technologies LP bought a new position in Amneal Pharmaceuticals in the 4th quarter worth approximately $259,000. 31.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

AMRX has been the subject of several analyst reports. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $9.00 to $12.00 in a report on Monday, February 24th. Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $10.80.

Insider Transactions at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gautam Patel sold 62,590 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90. Following the completion of the transaction, the director now owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. The trade was a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,240,000 shares of company stock valued at $43,754,000. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $8.66 on Friday. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.18 and a 52-week high of $9.48. The company has a market capitalization of $2.68 billion, a P/E ratio of -12.74 and a beta of 1.05. The company has a fifty day moving average of $8.38 and a 200-day moving average of $8.37.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same period in the prior year, the firm posted $0.14 earnings per share. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.